“Disease X could emerge suddenly and have deadly consquences—we’ve seen this happen with Ebola, MERS coronavirus, Zika, and countless other diseases. That’s why we’re striving to develop rapid-response vaccine platforms—like CureVac’s mRNA technology—to defend against these unknown pathogens. CEPI has now established partnership agreements totaling more than $50 million in three such platforms”.
It seems that the third mRNA vaccine company is BioNTech.
Johnson & Johnson appears to be using a more traditional approach in which the virus is inactivated so it can’t replicate but can still express viral proteins. The approach takes a little longer for both the development and manufacturing scale-up steps. On the plus side, Johnson & Johnson’s slow-but-steady approach could create a vaccine with a better immune response.
There’s a forth company with Inovio Pharm that also develops a COVID-19 vaccine. It’s technology is based on delievering DNA based.
I have the impression that the mRNA/DNA ways of vaccine delievery allow for faster development of a vaccine then the old fashioned protein based way.
From last year: From CEPI awards US$ 34M contract to CureVac to advance The RNA Printer™
It seems that the third mRNA vaccine company is BioNTech.
It seems that Johnson & Johnson is still developing a vaccine the traditional way:
There’s a forth company with Inovio Pharm that also develops a COVID-19 vaccine. It’s technology is based on delievering DNA based.
I have the impression that the mRNA/DNA ways of vaccine delievery allow for faster development of a vaccine then the old fashioned protein based way.